CY1109766T1 - Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv - Google Patents

Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv

Info

Publication number
CY1109766T1
CY1109766T1 CY20101100099T CY101100099T CY1109766T1 CY 1109766 T1 CY1109766 T1 CY 1109766T1 CY 20101100099 T CY20101100099 T CY 20101100099T CY 101100099 T CY101100099 T CY 101100099T CY 1109766 T1 CY1109766 T1 CY 1109766T1
Authority
CY
Cyprus
Prior art keywords
protease inhibitors
hiv protease
azapeptide derivatives
azapeptide
derivatives
Prior art date
Application number
CY20101100099T
Other languages
English (en)
Inventor
Scott L Harbeson
Roger D Tung
Original Assignee
Concert Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals, Inc. filed Critical Concert Pharmaceuticals, Inc.
Publication of CY1109766T1 publication Critical patent/CY1109766T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

Η εφεύρεση αυτή αφορά νέες ενώσεις του Τύπου lb:
CY20101100099T 2007-06-12 2010-02-03 Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv CY1109766T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29
EP08252023A EP2003120B9 (en) 2007-06-12 2008-06-12 Azapeptide derivatives as HIV protease inhibitors

Publications (1)

Publication Number Publication Date
CY1109766T1 true CY1109766T1 (el) 2014-09-10

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100099T CY1109766T1 (el) 2007-06-12 2010-02-03 Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv

Country Status (26)

Country Link
US (4) US20090036357A1 (el)
EP (3) EP2003120B9 (el)
JP (1) JP2010529196A (el)
KR (2) KR101185899B1 (el)
CN (2) CN102424668A (el)
AR (1) AR066972A1 (el)
AT (2) ATE447554T1 (el)
AU (1) AU2008267048C1 (el)
BR (2) BRPI0813911A2 (el)
CA (1) CA2692028C (el)
CO (1) CO6241121A2 (el)
CY (1) CY1109766T1 (el)
DE (1) DE602008000255D1 (el)
DK (1) DK2003120T3 (el)
ES (3) ES2356334T3 (el)
HK (2) HK1136576A1 (el)
HR (1) HRP20100065T1 (el)
MX (1) MX2009013565A (el)
PL (1) PL2003120T3 (el)
PT (1) PT2003120E (el)
RS (1) RS51226B (el)
RU (2) RU2448958C2 (el)
SI (1) SI2003120T1 (el)
TW (1) TW200908970A (el)
WO (1) WO2008156632A1 (el)
ZA (1) ZA200909079B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200835693A (en) * 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
WO2008156632A1 (en) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
EP2334318B1 (en) * 2008-10-06 2016-02-10 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
US8784858B2 (en) * 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
DK3135656T3 (en) 2011-06-20 2019-04-23 H Lundbeck As DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF schizophrenia
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-（2-吡啶基）苄基]-肼羧酸叔丁酯的制备方法
HRP20211687T1 (hr) * 2015-12-02 2022-03-04 Merck Sharp & Dohme Corp. Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
AR117600A1 (es) * 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
AU2021257341A1 (en) * 2020-04-16 2022-11-17 The Medical College Of Wisconsin, Inc. Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206497B1 (en) 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
KR100333016B1 (ko) 1992-12-29 2002-11-22 아보트 러보러터리즈 레트로바이러스성프로테아제억제화합물,이의제조방법및이를함유하는약제학적조성물
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ES2193921T3 (es) * 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
ATE282428T1 (de) 2001-05-03 2004-12-15 Hoffmann La Roche Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
CA2458807A1 (en) * 2001-08-31 2003-03-13 Bristol-Myers Squibb Company Use of atazanavir in hiv therapy
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2516642C (en) 2003-02-21 2010-11-23 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CA2571726C (en) * 2004-07-06 2013-05-21 Abbott Laboratories Prodrugs of hiv protease inhibitors
CN101076319A (zh) 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
CA2588466A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008156632A1 (en) * 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US20090076097A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
US8158805B2 (en) 2012-04-17
CN102424668A (zh) 2012-04-25
SI2003120T1 (sl) 2010-03-31
RS51226B (sr) 2010-12-31
RU2012101881A (ru) 2013-07-27
KR101185899B1 (ko) 2012-09-27
PL2003120T3 (pl) 2010-04-30
EP2116532A1 (en) 2009-11-11
RU2448958C2 (ru) 2012-04-27
HK1136576A1 (en) 2010-07-02
TW200908970A (en) 2009-03-01
ATE536343T1 (de) 2011-12-15
ES2356334T3 (es) 2011-04-07
AU2008267048C1 (en) 2013-01-17
CA2692028C (en) 2013-06-04
BRPI0813911A2 (pt) 2012-02-22
EP2003120B9 (en) 2010-06-02
EP2322509B1 (en) 2012-08-22
BRPI0823520A2 (pt) 2013-12-17
ZA200909079B (en) 2011-05-25
AU2008267048A1 (en) 2008-12-24
CA2692028A1 (en) 2008-12-24
PT2003120E (pt) 2010-02-11
ES2394952T3 (es) 2013-02-07
HK1127345A1 (en) 2009-09-25
DK2003120T3 (da) 2010-03-15
US20090036357A1 (en) 2009-02-05
KR20120029480A (ko) 2012-03-26
EP2003120B1 (en) 2009-11-04
ATE447554T1 (de) 2009-11-15
JP2010529196A (ja) 2010-08-26
MX2009013565A (es) 2010-06-02
HRP20100065T1 (hr) 2010-03-31
RU2010100821A (ru) 2011-07-20
US20120165288A1 (en) 2012-06-28
US20130041156A1 (en) 2013-02-14
AU2008267048B2 (en) 2012-05-31
US20110009355A1 (en) 2011-01-13
KR20100020033A (ko) 2010-02-19
DE602008000255D1 (de) 2009-12-17
CN101711237B (zh) 2013-08-07
CN101711237A (zh) 2010-05-19
AR066972A1 (es) 2009-09-23
WO2008156632A1 (en) 2008-12-24
CO6241121A2 (es) 2011-01-20
ES2395137T3 (es) 2013-02-08
EP2322509A1 (en) 2011-05-18
US8258309B2 (en) 2012-09-04
EP2116532B1 (en) 2011-12-07
EP2003120A1 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
CY1109766T1 (el) Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv
CY1121265T1 (el) Παραγωγα πιπεριδινονης ως αναστολεις της mdm2 για την θεραπευτικη αγωγη του καρκινου
CY1112221T1 (el) S-τριαζολυλ αλφα-μερκαπτοακετανιλιδες ως αναστολεις της αντιστροφης μεταγραφασης του ηιv
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
CR20130369A (es) Novedosos derivados heterocíclicos
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
CR20130537A (es) Compuestos heterocíclicos como inhibidores de cinasas
CY1113727T1 (el) Παραγωγα πυριδιν-4-υλ ως ανοσορυθμιστικοι παραγοντες
ATE552255T1 (de) 4-aminoindazole
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
BR112015004111A2 (pt) novos derivados bicíclicos
CR20120417A (es) Inhibidores de virus flaviviridae
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
CR10662A (es) Compuestos de metilpiridopirimidinona
ATE542798T1 (de) Organische verbindungen
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
EA201101026A1 (ru) Ингибиторы бета-секретазы
EA200702614A1 (ru) Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот
HRP20080554A2 (en) Process for preparation of hiv protease inhibitors
EA201100666A1 (ru) Тиоамидные соединения, способ их получения и способ их применения